President Donald Trump launched TrumpRx.gov on February 5, 2026, giving Americans direct online access to sharply discounted cash prices on more than 40 brand-name prescription drugs, including the blockbuster weight-loss medications Ozempic and Wegovy. During a primetime White House event, Trump announced that patients with valid prescriptions can now visit the federal portal to obtain coupons or manufacturer-linked discounts that slash monthly costs by 50 to 93 percent. Popular GLP-1 drugs, which have driven celebrity-driven demand for weight management, are prominently featured with Ozempic pens priced around $199 to $350 per month (down from a list price of $1,028) and Wegovy starting at $149 to $199 per month (down from $1,349).
The platform operates on a cash-pay model, meaning users print coupons or use integrated manufacturer channels to purchase medications at participating pharmacies without involving insurance. Patients browse an official list of covered drugs on the site, select their prescribed medication and dosage, and immediately access the discounted rate. Trump described the initiative as the largest single reduction in U.S. prescription drug prices in history, fulfilling a core 2024 campaign promise to end what he called Big Pharma price-gouging by enforcing Most Favored Nation pricing that matches the lowest rates paid in other developed countries.
TrumpRx.gov emphasizes convenience and transparency: no middlemen, no prior authorizations for these deals, and savings available the same day for those who already have a prescription. The site highlights insulin products like Lispro at $25 per month and fertility drugs like Cetrotide at $22.50 (down from $316), alongside the high-profile weight-loss options. Administration officials say more manufacturers are expected to join soon, expanding the list beyond the initial 43 medications.
Reaction online has been sharply divided. Supporters praised the tangible discounts as proof that Trump is delivering results where previous administrations failed, while critics pointed out that the program covers only a narrow selection of mostly trendy brand-name drugs rather than the generics and staples that most patients rely on daily. Some users noted that competing services like Mark Cuban’s Cost Plus Drugs or GoodRx already offer lower prices on certain medications, raising questions about how broadly transformative the new portal will prove.
The launch revives Trump’s earlier Most Favored Nation executive orders from 2020, which courts blocked during his first term. By routing discounts through coupons and direct manufacturer agreements rather than mandating price controls across insurers, the administration appears to have sidestepped those legal hurdles. Whether TrumpRx.gov evolves into a comprehensive solution or remains a targeted intervention for high-visibility drugs will determine its long-term impact on the nation’s ongoing struggle with prescription costs.
